Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Evaluation of race and ethnicity disparities in outcome studies of CYP2C19 genotype-guided antiplatelet therapy
Anh B. Nguyen, Larisa H. Cavallari, Joseph S. Rossi, et al.
Frontiers in Cardiovascular Medicine (2022) Vol. 9
Open Access | Times Cited: 28

Showing 1-25 of 28 citing articles:

CYP2C19 Genetic Testing for Oral P2Y12 Inhibitor Therapy: A Scientific Statement From the American Heart Association
Naveen L. Pereira, Sharon Cresci, Dominick J. Angiolillo, et al.
Circulation (2024) Vol. 150, Iss. 6
Closed Access | Times Cited: 23
CYP2C19 Genotype‐Guided Antiplatelet Therapy and Clinical Outcomes in Patients Undergoing a Neurointerventional Procedure
Kayla R. Tunehag, Ashton F. Pearce, Layna P. Fox, et al.
Clinical and Translational Science (2025) Vol. 18, Iss. 1
Open Access | Times Cited: 1
From genes to drugs: CYP2C19 and pharmacogenetics in clinical practice
Qamar Shubbar, Aminah Alchakee, Khaled Walid Issa, et al.
Frontiers in Pharmacology (2024) Vol. 15
Open Access | Times Cited: 7
International Consensus Statement on Platelet Function and Genetic Testing in Percutaneous Coronary Intervention
Dominick J. Angiolillo, Mattía Galli, Dimitrios Alexopoulos, et al.
КАРДИОЛОГИЯ УЗБЕКИСТАНА (2024) Vol. 17, Iss. 22, pp. 2639-2663
Closed Access | Times Cited: 6
Pharmacogenetics ofP2Y12receptor inhibitors
Cameron D. Thomas, Alexis K. Williams, Craig R. Lee, et al.
Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy (2023) Vol. 43, Iss. 2, pp. 158-175
Open Access | Times Cited: 12
Lack of Racial Disparities in Cangrelor Therapy in Patients Presenting With Acute Coronary Syndrome Undergoing Percutaneous Coronary Intervention
Waiel Abusnina, Kalyan R. Chitturi, Abhishek Chaturvedi, et al.
Catheterization and Cardiovascular Interventions (2025)
Closed Access
Effect of CYP2C19 Genotype on Outcomes of Treatment with Ticagrelor versus Clopidogrel in Acute Coronary Syndrome Patients with Diabetes Mellitus: A Analysis in a Large-Scale, Real-World Study
Hao Tian, Miaohan Qiu, Kun Na, et al.
European Journal of Pharmacology (2025), pp. 177546-177546
Closed Access
Managing Clopidogrel Resistance in Neurointervention: Surveying Current Approaches
Hyun Woo Kim, Ivo Bach, Juan Carlos Martinez Gutierrez, et al.
Stroke Vascular and Interventional Neurology (2024) Vol. 4, Iss. 4
Open Access | Times Cited: 3
CYP2C19 Genotype Is Associated With Adverse Cardiovascular Outcomes in Black Patients Treated With Clopidogrel Undergoing Percutaneous Coronary Intervention
Kayla R. Tunehag, Cameron D. Thomas, Francesco Franchi, et al.
Journal of the American Heart Association (2024) Vol. 13, Iss. 12
Open Access | Times Cited: 3
Genotype-Guided Antiplatelet Therapy
Wout W. A. van den Broek, Brenden Ingraham, Naveen L. Pereira, et al.
Journal of the American College of Cardiology (2024) Vol. 84, Iss. 12, pp. 1107-1118
Closed Access | Times Cited: 2
Evaluating the Effect of Estimating Renal Function With the CKD‐EPI 2021 Equation on the ABCD‐GENE Score for Clopidogrel Response Prediction
Maryam Jamal AlSaeed, Cameron D. Thomas, Francesco Franchi, et al.
Clinical Pharmacology & Therapeutics (2024)
Closed Access | Times Cited: 2
Real-world evaluation of CYP2C19 guided antiplatelet therapy in patients undergoing intracranial aneurysm repair
Layna P. Fox, Kayla R. Tunehag, Anh B. Nguyen, et al.
Pharmacogenomics (2024), pp. 1-11
Closed Access | Times Cited: 2
Evaluation of Potential Racial Disparities inCYP2C19‐Guided P2Y12Inhibitor Prescribing After Percutaneous Coronary Intervention
Larisa H. Cavallari, Nita A. Limdi, Amber L. Beitelshees, et al.
Clinical Pharmacology & Therapeutics (2022) Vol. 113, Iss. 3, pp. 615-623
Open Access | Times Cited: 8
The Clinical Implementation of CYP2C19 Genotyping in Patients with an Acute Coronary Syndrome: Insights From the FORCE-ACS Registry
Jaouad Azzahhafi, Wout W. A. van den Broek, Dean R.P.P. Chan Pin Yin, et al.
Journal of Cardiovascular Pharmacology and Therapeutics (2023) Vol. 28
Open Access | Times Cited: 4
The Impact of Sex on Antiplatelet and Anticoagulant Thromboprophylaxis in Patients with Peripheral Artery Disease Post-revascularization
Sasha Suarez, Aniket Agrawal, Shiv Patel, et al.
Annals of Surgery (2024)
Closed Access | Times Cited: 1
Precision Antiplatelet Therapy after Percutaneous Coronary Intervention (Precision PCI) Registry – Informing optimal antiplatelet strategies
Larisa H. Cavallari, Craig R. Lee, Francesco Franchi, et al.
Clinical and Translational Science (2024) Vol. 17, Iss. 8
Open Access | Times Cited: 1
Demographic diversity in platelet function and response to antiplatelet therapy
Kanika Jain, Tarun Tyagi, Sean X. Gu, et al.
Trends in Pharmacological Sciences (2024)
Closed Access | Times Cited: 1
Guided antiplatelet therapy with P2Y12 antagonists in patients undergoing percutaneous coronary intervention: 3 systematic reviews with meta-analyses of randomized controlled trials with homogeneous design
Simone Birocchi, Matteo Rocchetti, Alessandro Minardi, et al.
medRxiv (Cold Spring Harbor Laboratory) (2023)
Open Access | Times Cited: 3
Antiplatelet efficacy of ticagrelor versus clopidogrel in Mediterranean patients with diabetes mellitus and chronic coronary syndromes: A crossover pharmacodynamic investigation
Ana Lucrecia Marcano, Montserrat Gracida, Gerard Roura, et al.
Frontiers in Cardiovascular Medicine (2022) Vol. 9
Open Access | Times Cited: 3
Genetic Determinants of Response to P2Y12 Inhibitors and Clinical Implications
Larisa H. Cavallari, James C. Coons
Interventional Cardiology Clinics (2024) Vol. 13, Iss. 4, pp. 469-481
Closed Access
Insights into pharmacogenetics, drug-gene interactions, and drug-drug-gene interactions
Laura Russell, Katrina G. Claw, Kaja M. Aagaard, et al.
Drug Metabolism Reviews (2024), pp. 1-19
Closed Access
Genotype-Guided De-Escalation of DAPT
Larisa H. Cavallari, Francesco Franchi
КАРДИОЛОГИЯ УЗБЕКИСТАНА (2024) Vol. 17, Iss. 17, pp. 2008-2010
Closed Access
CYP2C19 Genotype-Guided Antiplatelet Therapy in Stroke Patients—Is It Ready for Prime Time?
Danwei Shao, Joyce Mosha, Rajiv Patel, et al.
Cardiovascular Drugs and Therapy (2024)
Closed Access
Association of CYP2C19*2 c.681G>A (rs4244285) Loss-of-function Allele with Cardiovascular Disease Risk in the Kosovo Population
N Elshani, K Ukella, Stojovska M Staninova, et al.
Balkan Journal of Medical Genetics (2024) Vol. 27, Iss. 2, pp. 77-85
Open Access
Rates of 30-Day and 90-Day Readmission Between Genotype-Optimal and Genotype-Suboptimal Antiplatelet Therapy Prescribing After Percutaneous Coronary Intervention
Kevin K Cheng, Christian San Andres, Emen Salam, et al.
The American Journal of Cardiology (2023) Vol. 202, pp. 218-222
Closed Access | Times Cited: 1
Page 1 - Next Page

Scroll to top